Navigation Links
NeurogesX Announces Publication of Phase 3 Data for QUTENZA(TM) (NGX-4010) in Postherpetic Neuralgia (PHN) by The Lancet Neurology
Date:1/12/2009

ans with regard to seeking potential development partners for its early-stage product pipeline. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, NeurogesX' product candidates may have unexpected adverse side effects or inadequate therapeutic efficacy; positive results in clinical trials may not be sufficient to obtain FDA or European regulatory approval; any regulatory approvals which are received may offer more limited indications than anticipated; physician or patient reluctance to use Qutenza or NGX-1998, if approved, or the inability of physicians to obtain sufficient reimbursement for such procedures; potential alternative therapies; maintaining adequate patent or trade secret protection without violating the intellectual property rights of others; and other difficulties or delays in, clinical development, obtaining regulatory approval, market acceptance and commercialization of NeurogesX' product candidates and the advantages of NeurogesX' product candidates over other pain therapies. For further information regarding these and other risks related to NeurogesX' business, investors should consult NeurogesX' filings with the Securities and Exchange Commission.

    NeurogesX, Inc.
    Stephen Ghiglieri
    Chief Financial Officer
    (650) 358-3310

    The Ruth Group
    Stephanie Carrington / Sara Ephraim (investors)
    (646) 536-7017 / 7002
    scarrington@theruthgroup.com
    sephraim@theruthgroup.com

    Jason Rando (media)
    (646) 536-7025
    jrando@theruthgroup.com


'/>"/>
SOURCE NeurogesX, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. NeurogesX Initiates Dosing in Phase 1 Clinical Trial for NGX-1998 Capsaicin Liquid Formulation
2. NeurogesX Announces Publication of NGX-4010 Phase 3 HIV-Neuropathy Study Results in Neurology
3. NeurogesX Announces Preliminary Results from Second Phase 3 Clinical Trial in HIV-DSP
4. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
5. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
6. NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
7. Pulmo BioTech Inc. Announces Dual Listing on Frankfurt Borse
8. Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference
9. Anesiva Announces FDA Approval of Supplemental New Drug Application to Expand Zingo(TM) Indication
10. ProUroCare Medical Inc. Announces Pricing of Equity Offering
11. Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... /CNW/ -   The ... Canada tests confirmed it contains two undeclared amphetamine-like drug ... The distributor, Empire Health Distribution of Terrebonne, ... stores across Canada .  Jetfuel Superburn ... loss and increased energy. What consumers ...
(Date:12/24/2014)... 24, 2014  Novastem, a leader in regenerative ... in its study for ischemic stroke at Clinica ... ischemic strokes account for 87 percent of all ... in the study, entitled "Internal Research Protocol in ... Stem Cells and Intrathecal Administration of Neural Stem ...
(Date:12/24/2014)... 24, 2014  Actavis plc (NYSE: ... received a complete response letter from the U.S. ... Drug Application (NDA) for the fixed-dose combination (FDC) ... hypertension.   Photo - http://photos.prnewswire.com/prnh/20130124/NY47381LOGO ... the receipt of a complete response letter, Actavis ...
Breaking Medicine Technology:"Jetfuel Superburn" recalled after Health Canada tests find undeclared drug ingredients 2Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 2Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 3Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 4Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 2Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 3Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 4
... 4, 2011 Cumberland Pharmaceuticals Inc. (Nasdaq: ... new senior credit agreement with Bank of America.  Pursuant to ... of credit to $10 million, which is expandable to $20 ... has been extended to December 2014. The new ...
... Mo., Aug. 4, 2011 Purdue Pharma, L.P., ... antiseptic to Children International , a U.S.-based ... world. To view the multimedia assets ... (Photo: http://photos.prnewswire.com/prnh/20110804/MM46982 ...
Cached Medicine Technology:Cumberland Pharmaceuticals Inks New Bank Financing Deal With Bank of America 2Purdue Pharmaceuticals Donates Medical Supplies to Protect Poor Children From Infection 2Purdue Pharmaceuticals Donates Medical Supplies to Protect Poor Children From Infection 3
(Date:12/24/2014)... Connie Casad, MD, a well-known and respected gynecologist, ... years of practice experience in Dallas, Texas, has announced ... dietary detoxification. The second study is scheduled to begin ... test patients who just completed a 21-day detoxification regimen. ... conducting the study, Dr. Casad said, "About 10 years ...
(Date:12/24/2014)... 2014 The federal court overseeing ... blood thinner caused life-threatening episodes of internal bleeding ... for the proceeding, Bernstein Liebhard LLP reports. According ... plans to select lawyers to serve as Liaison ... appointing a Plaintiffs’ Steering Committee, which will coordinate ...
(Date:12/24/2014)... (PRWEB) December 25, 2014 BambooIndustry.com a ... for many years. Today, the company announces its ... a special offer on these new products. , Bamboo ... renewable bamboo. The multiple layer bamboo panel board features ... both strong and emissions free. The bamboo panel consists ...
(Date:12/24/2014)... Dec. 24, 2014 (HealthDay News) -- Adults who ... risk of migraine headaches, suggests a study published ... . "Childhood maltreatment can have long-lasting effects, ... in adulthood," study author Dawn Buse, director of ... York City, said in a journal news release. ...
(Date:12/24/2014)... 2014 Gluten, a protein found predominately ... have an intolerance to gluten, causing side effects that ... headaches, joint pain and fatigue. For this reason, Diet ... that deliver safe and fast weight loss while teaching ... gluten allergy reaction. These gluten free diet plans combine ...
Breaking Medicine News(10 mins):Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 2Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 3Health News:Court Overseeing Federal Xarelto Lawsuits Issues Coordination Order, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal Xarelto Lawsuits Issues Coordination Order, Bernstein Liebhard LLP Reports 3Health News:Bamboo Flooring Company Bambooindustry.com Introduces Its Multiple Layer Bamboo Panel Board Collection 2Health News:Abuse in Childhood Tied to Migraines in Adulthood 2Health News:Diet Doc Adds Gluten Free Diet Plans to Their Stable of Specialized Weight Loss Programs 2Health News:Diet Doc Adds Gluten Free Diet Plans to Their Stable of Specialized Weight Loss Programs 3
... locking self locking fasteners are helping the electrical industry combat vibration ... design innovation. , ... (PRWEB) July 2, 2008 -- ... in soft materials prone to stripping or joint failure, self ...
... caring begun 29,years ago by a small group of friends ... fundraisers, thanks to the enthusiastic support of,women who see the ... The 29th annual Twilight Gathering, hosted by the Women,s ... p.m. at the home,of WCP President Carol Walters in Milford. ...
... Enthusiasm for event grows in the face of widespread budget cuts ... Area HIV/AIDS service ... Foundation,and AIDS Walk San Francisco announced today that the number of ... in,Golden Gate Park, July 20th, will expand from 42 to more ...
... Delaying childbirth has substantially contributed to recent rises in ... week by scientists at Cambridge University. , The findings ... Scottish data performed by a team under Professor Gordon ... , The team examined more than 500,000 entries ...
... help treat patients with cancer, depression, drug abuse, study ... spiritual effects of a substance in "sacred mushrooms" can ... , The scientists said their investigations may lead to ... cancer, depression and drug dependence. , In a previous ...
... Inc.,(Nasdaq: SUPG ), a pharmaceutical company dedicated ... for solid tumors and,hematological malignancies, today announced that ... is scheduled to present at the,Collins Stewart Growth ... Oriental Hotel in New York City., SuperGen,s ...
Cached Medicine News:Health News:Innovative Self Locking Threaded Fasteners Provide New Electrical Design Options 2Health News:Area Women Gather in Milford on July 10 to Further the Mission of Women's Caring Program 2Health News:AIDS Walk San Francisco Boosts Number of Teams and Benefiting Agencies 2Health News:AIDS Walk San Francisco Boosts Number of Teams and Benefiting Agencies 3Health News:Major rise in Caesarean sections linked to impaired womb function with age 2Health News:Hallucinogen Gives Lasting Spiritual Boost 2Health News:SuperGen to Present at the Collins Stewart Growth Conference on July 9, 2008 2
Adjust-A-Tip cautery....
Thru cut kerrison style punch 30 deg, 2.75 X 1.4 mm cut, 110 working length....
3 mm, 130 degree upwards cutting, detachable....
Sabre 180 is a powerful niche generator....
Medicine Products: